AU2001296558A1 - Inhibitors of angiogenesis and tumor growth for local and systemic administration - Google Patents
Inhibitors of angiogenesis and tumor growth for local and systemic administrationInfo
- Publication number
- AU2001296558A1 AU2001296558A1 AU2001296558A AU9655801A AU2001296558A1 AU 2001296558 A1 AU2001296558 A1 AU 2001296558A1 AU 2001296558 A AU2001296558 A AU 2001296558A AU 9655801 A AU9655801 A AU 9655801A AU 2001296558 A1 AU2001296558 A1 AU 2001296558A1
- Authority
- AU
- Australia
- Prior art keywords
- angiogenesis
- inhibitors
- local
- tumor growth
- systemic administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000033115 angiogenesis Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 238000007910 systemic administration Methods 0.000 title 1
- 230000004614 tumor growth Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23742900P | 2000-10-03 | 2000-10-03 | |
US60237429 | 2000-10-03 | ||
PCT/US2001/030986 WO2002028387A1 (en) | 2000-10-03 | 2001-10-03 | Inhibitors of angiogenesis and tumor growth for local and systemic administration |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001296558A1 true AU2001296558A1 (en) | 2002-04-15 |
Family
ID=22893665
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001296558A Abandoned AU2001296558A1 (en) | 2000-10-03 | 2001-10-03 | Inhibitors of angiogenesis and tumor growth for local and systemic administration |
Country Status (3)
Country | Link |
---|---|
US (1) | US6696483B2 (en) |
AU (1) | AU2001296558A1 (en) |
WO (1) | WO2002028387A1 (en) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL414997A1 (en) * | 2001-02-19 | 2016-02-29 | Novartis Ag | Application of 40-O-(2-hydroxyethyl)-rapamycin for treatment of solid kidney tumors |
AU2003261354A1 (en) * | 2002-08-02 | 2004-02-23 | The Regents Of The University Of California | New uses for inhibitors of inosine monophosphate dehydrogenase |
UY27412A1 (en) * | 2002-08-12 | 2003-06-30 | Carlson Internat Inc | A NEW PRODUCT FOR TICKET FIGHTING AND THE PREPAACINN PROCESS. |
PT1539157E (en) | 2002-09-18 | 2013-10-04 | Univ Pennsylvania | Rapamycin for use in inhibiting or preventing choroidal neovascularization |
US20050026893A1 (en) * | 2003-05-30 | 2005-02-03 | Kosan Biosciences, Inc. | Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants |
US7691838B2 (en) * | 2003-05-30 | 2010-04-06 | Kosan Biosciences Incorporated | Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics |
US20050054589A1 (en) * | 2003-05-30 | 2005-03-10 | Kosan Biosciences, Inc. | Method for treating diseases using HSP90-inhibiting agents in combination with antibiotics |
AU2004267956B2 (en) | 2003-09-03 | 2010-09-16 | Miscon Trading S.A. | Methods for the treatment of endometriosis |
PT1729770E (en) * | 2004-03-15 | 2010-02-08 | Sunesis Pharmaceuticals Inc | Sns-595 and methods of using the same |
US7795205B2 (en) * | 2004-04-12 | 2010-09-14 | Canyon Pharmaceuticals, Inc. | Methods for effecting regression of tumor mass and size in a metastasized pancreatic tumor |
US20050249685A1 (en) * | 2004-04-27 | 2005-11-10 | Natalia Botchkareva | Reduction of hair growth |
WO2006009840A1 (en) * | 2004-06-21 | 2006-01-26 | Hutchison Medipharma Enterprises Limited | Benzoquinone compounds as a anti-cancer agents |
CN1875959B (en) * | 2004-10-14 | 2010-05-12 | 孔庆忠 | An anticancer pharmaceutical composition |
JP2008522735A (en) * | 2004-12-08 | 2008-07-03 | パーバシス セラピューティクス, インコーポレイテッド | Methods and compositions for enhancing vascular access |
MX2007007622A (en) * | 2004-12-22 | 2007-08-03 | Gillette Co | Reduction of hair growth. |
BRPI0608152A2 (en) | 2005-02-09 | 2009-11-10 | Macusight Inc | eye care formulations |
CA2605080A1 (en) * | 2005-04-21 | 2006-11-02 | Massachusetts Institute Of Technology | Materials and methods for altering an immune response to exogenous and endogenous immunogens, including syngeneic and non-syngeneic cells, tissues or organs |
AU2006262682B2 (en) * | 2005-06-21 | 2012-07-05 | Shire Regenerative Medicine, Inc. | Methods and compositions for enhancing vascular access |
US8580814B2 (en) * | 2006-04-03 | 2013-11-12 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
US20100204783A1 (en) * | 2005-12-06 | 2010-08-12 | Helen Marie Nugent | Methods and compositions for enhancing vascular access |
WO2007092414A2 (en) * | 2006-02-06 | 2007-08-16 | Lixte Biotechnology Holdings, Inc. | Use of phosphatases to treat tumors overexpressing n-cor |
WO2007092620A2 (en) | 2006-02-09 | 2007-08-16 | Macusight, Inc. | Stable formulations, and methods of their preparation and use |
US8658633B2 (en) * | 2006-02-16 | 2014-02-25 | Massachusetts Eye And Ear Infirmary | Methods and compositions for treating conditions of the eye |
CA2645488C (en) | 2006-03-23 | 2014-09-02 | Macusight, Inc. | Formulations comprising rapamycin and methods using same for vascular permeability-related diseases or conditions |
US20090018142A9 (en) * | 2006-05-02 | 2009-01-15 | Zhengping Zhuang | Use of phosphatases to treat tumors overexpressing N-CoR |
JP2009539994A (en) | 2006-06-12 | 2009-11-19 | サネシス ファーマシューティカルズ, インコーポレイテッド | Compounds and compositions for the treatment of cancer |
EP3025712A1 (en) * | 2006-08-02 | 2016-06-01 | Sunesis Pharmaceuticals, Inc. | Combined use of (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid and cytarabine (ara-c) for the treatment of leukemia |
CA2668621A1 (en) * | 2006-11-07 | 2008-05-15 | Pervasis Therapeutics, Inc. | Materials and methods for treating and managing angiogenesis-mediated diseases |
CN101662939B (en) * | 2007-02-06 | 2015-11-25 | 利克斯特生物技术公司 | Oxa-bicyclo heptane and oxabicyclo heptene, their preparation and purposes |
EP2141995B1 (en) | 2007-03-27 | 2014-11-05 | Perscitus Biosciences, LLC | Compositions and their uses in protecting cells from toxic exposures |
TWI407971B (en) * | 2007-03-30 | 2013-09-11 | Nitto Denko Corp | Cancer cells and tumor-related fibroblasts |
EP2185173A4 (en) * | 2007-08-03 | 2011-01-12 | Lixte Biotechnology Inc | Use of phosphatases to treat neuroblastomas and medullogastomas |
CA2700857C (en) | 2007-10-01 | 2016-08-02 | John S. Kovach | Hdac inhibitors |
US8518872B2 (en) * | 2007-10-22 | 2013-08-27 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-OXO-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination therapy |
US9994585B2 (en) | 2007-12-31 | 2018-06-12 | Aphios Corporation | Transplantation therapies |
WO2010147612A1 (en) | 2009-06-18 | 2010-12-23 | Lixte Biotechnology, Inc. | Methods of modulating cell regulation by inhibiting p53 |
WO2010014220A1 (en) | 2008-08-01 | 2010-02-04 | Lixte Biotechnology, Inc. | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases |
EP2309853A4 (en) * | 2008-08-01 | 2012-04-25 | Lixte Biotechnology Inc | Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase |
US8227473B2 (en) | 2008-08-01 | 2012-07-24 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
US9351988B2 (en) | 2011-05-02 | 2016-05-31 | Universite De Geneve | Macrocyclic lactones and use thereof |
US9034347B2 (en) | 2011-12-19 | 2015-05-19 | Arphios Corporation | Drug delivery system and method for the treatment of neuro-degenerative disease |
EP2925314B1 (en) * | 2012-11-28 | 2020-04-01 | Aphios Corporation | Combination therapeutics and methods for the treatment of neurodegenerative and other diseases |
US20140308236A1 (en) * | 2013-01-08 | 2014-10-16 | Technion Research And Development Foundation Ltd. | Antimicrobial composition and uses thereof |
EA201591931A1 (en) | 2013-04-09 | 2016-05-31 | Ликсте Байотекнолоджи, Инк. | COMPOSITIONS OF OXABICYCLOPTANES AND OXABITICLOCEPTENS |
US11369588B2 (en) * | 2014-03-20 | 2022-06-28 | The Trustees Of Princeton University | NADPH production by the 10-formyl-THF pathway, and its use in the diagnosis and treatment of disease |
JP6843774B2 (en) * | 2015-06-23 | 2021-03-17 | ファーティマ・ベナジール・ジャハンギル・アリ | Plant-based pigments for staining biological samples, their extraction methods and uses |
US11058700B2 (en) * | 2015-10-28 | 2021-07-13 | City Of Hope | Macrocyclic lactones and uses thereof as modulators of purinergic receptors |
CN114886842A (en) * | 2022-05-24 | 2022-08-12 | 吴丽莎 | Preparation method and application of brefeldin A ointment |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4062921A (en) | 1976-02-19 | 1977-12-13 | University Of Delaware | Solvents for and purification of chitin |
US4059457A (en) | 1976-02-19 | 1977-11-22 | The University Of Delaware | Chitin solution |
US4464389A (en) | 1982-10-20 | 1984-08-07 | Sri International | Esters of retinoic acid and pentaerythritol and monobenzal acetals thereof |
DE3247379A1 (en) | 1982-12-22 | 1984-06-28 | Basf Ag, 6700 Ludwigshafen | BREFELDIN-A DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE FOR COMBATING UNWANTED PLANT GROWTH |
US5428163A (en) | 1986-12-31 | 1995-06-27 | Mills; Randell L. | Prodrugs for selective drug delivery |
US4873092A (en) | 1987-05-21 | 1989-10-10 | Murata Kikai Kabushiki Kaisha | Slow-releasing preparation |
US5510418A (en) | 1988-11-21 | 1996-04-23 | Collagen Corporation | Glycosaminoglycan-synthetic polymer conjugates |
DE3903797A1 (en) | 1989-02-09 | 1990-08-16 | Hoechst Ag | METHOD FOR THE PRODUCTION OF ACTIVATED CHITOSANS AND THE USE THEREOF IN THE PRODUCTION OF CHITOSAN DERIVATIVES |
US5439446A (en) | 1994-06-30 | 1995-08-08 | Boston Scientific Corporation | Stent and therapeutic delivery system |
US5580575A (en) | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
US5242932A (en) | 1991-12-17 | 1993-09-07 | The Rockefeller University | Treatment of amyloidosis associated with alzheimer disease |
JPH04185601A (en) | 1990-11-20 | 1992-07-02 | Unitika Ltd | Sustained release preparation containing platinum anticancer drug |
IT1243390B (en) | 1990-11-22 | 1994-06-10 | Vectorpharma Int | PHARMACEUTICAL COMPOSITIONS IN THE FORM OF PARTICLES SUITABLE FOR THE CONTROLLED RELEASE OF PHARMACOLOGICALLY ACTIVE SUBSTANCES AND PROCEDURE FOR THEIR PREPARATION. |
GR920100122A (en) | 1991-04-05 | 1993-03-16 | Ethicon Inc | Ionically crosslinked carboxyl-containing polysaccharides for adhension prevention. |
ATE177629T1 (en) | 1991-04-10 | 1999-04-15 | Yu Ruey J | USE OF COMPOSITIONS CONTAINING 2-HYDROXYCARBONIC ACID OR DERIVATIVES THEREOF FOR RELIEVING OCEAN NAIL CHANGES |
WO1993025225A1 (en) | 1992-06-17 | 1993-12-23 | University Of Massachusetts Medical Center | Liposomal formulations for administering to cancer patients |
US5871710A (en) | 1992-09-04 | 1999-02-16 | The General Hospital Corporation | Graft co-polymer adducts of platinum (II) compounds |
US5744155A (en) | 1993-08-13 | 1998-04-28 | Friedman; Doron | Bioadhesive emulsion preparations for enhanced drug delivery |
US5846952A (en) | 1993-12-01 | 1998-12-08 | Marine Polymer Technologies, Inc. | Methods and compositions for poly-β-1-4-N-acetylglucosamine drug delivery |
US5837682A (en) | 1996-03-08 | 1998-11-17 | The Children's Medical Center Corporation | Angiostatin fragments and method of use |
US5696154A (en) | 1994-06-29 | 1997-12-09 | The United States Of America As Represented By The Department Of Health And Human Services | Brefeldin A derivatives and their utility in the treatment of cancer |
US5637688A (en) * | 1994-12-13 | 1997-06-10 | Eli Lilly And Company | Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride |
US5843925A (en) | 1994-12-13 | 1998-12-01 | American Cyanamid Company | Methods for inhibiting angiogenesis, proliferation of endothelial or tumor cells and tumor growth |
US5786391A (en) | 1995-01-11 | 1998-07-28 | Cornell Research Foundation, Inc. | Regulating gene expression using retinoids with Ch2 OH or related groups at the side chain terminal position |
US5762903A (en) | 1995-03-10 | 1998-06-09 | Korea Atomic Energy Research Institute | Radioactive chitosan complex for radiation therapy |
WO1996031237A2 (en) | 1995-04-04 | 1996-10-10 | Wound Healing Of Oklahoma | Cancer treatment by photodynamic therapy, in combination with an immunoadjuvant |
US5618837A (en) * | 1995-06-07 | 1997-04-08 | Zymogenetics, Inc. | PDGF antagonists III |
US5854205A (en) | 1995-10-23 | 1998-12-29 | The Children's Medical Center Corporation | Therapeutic antiangiogenic compositions and methods |
WO1997030705A1 (en) | 1996-02-21 | 1997-08-28 | Matrix Pharmaceutical, Inc. | Use of cell membrane permeants in the treatment of cellular proliferative diseases |
CA2253608A1 (en) | 1996-05-01 | 1997-11-06 | Louis Vignati | Therapeutic treatment for vegf related diseases |
US5932545A (en) | 1997-03-17 | 1999-08-03 | Abbott Laboratories | Antiangiogenic drug to treat cancer, arthritis and retinopathy |
WO1999031084A1 (en) * | 1997-12-18 | 1999-06-24 | Purdue Research Foundation | Brefeldin a derivatives |
JP2002525268A (en) | 1998-09-16 | 2002-08-13 | オンコファーマシューティカル, インコーポレイテッド | Treatment of oncological tumors with injectable formulations of Golgi apparatus blockers |
-
2001
- 2001-10-03 AU AU2001296558A patent/AU2001296558A1/en not_active Abandoned
- 2001-10-03 US US09/971,062 patent/US6696483B2/en not_active Expired - Fee Related
- 2001-10-03 WO PCT/US2001/030986 patent/WO2002028387A1/en active Search and Examination
Also Published As
Publication number | Publication date |
---|---|
WO2002028387A1 (en) | 2002-04-11 |
US20020061303A1 (en) | 2002-05-23 |
US6696483B2 (en) | 2004-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001296558A1 (en) | Inhibitors of angiogenesis and tumor growth for local and systemic administration | |
AU2001256975A1 (en) | Compositions and methods for inhibition of cancer invasion and angiogenesis | |
EP1097165A4 (en) | Novel inhibitors of angiogenesis and tumor growth | |
AU2001263229A1 (en) | Compositions and methods for administration of pharmacologically active compounds | |
AU2468401A (en) | Underreamer and method of use | |
AU2001235691A1 (en) | Use of paullone derivatives for making medicines | |
AU2600800A (en) | Promotion or inhibition of angiogenesis and cardiovascularization | |
AU2001273116A1 (en) | Semiconductor device and method of formation | |
AU2001244355A1 (en) | Heterobiarylsulphonamides and their use as pde 7 inhibitors | |
AU7079700A (en) | Improved stable formulations of ace inhibitors, and methods for preparation thereof | |
AU2001270778A1 (en) | Production, stabilisation and use of reduced forms of pharmaceutical compounds | |
AU2001266838A1 (en) | Inhibitors of matriptase for the treatment of cancer | |
AU2596700A (en) | Promotion or inhibition of angiogenesis and cardiovascularization | |
AU4825300A (en) | Methods for inhibiting cutaneous inflammation and hyperpigmentation | |
AU2001275707A1 (en) | Use of panaxatriol for stimulation angiogenesis | |
AU2001230898A1 (en) | Formulations and methods for administration of pharmacologically or biologicallyactive compounds | |
AU2002220735A1 (en) | Substituted derivatives of aminofuran-2-yl-acetic acid and aminothien-2-yl-acetic acid and the use thereof for treating migraines and pain | |
AU2001241771A1 (en) | Use of avocado-soybean unsaponifiable preparations | |
AU2001280588A1 (en) | Methods of modulating angiogenesis | |
AU2001251631A1 (en) | Hydrazide and alkoxyamide angiogenesis inhibitors | |
AU2002218084A1 (en) | Inhibitors of thromboxane formation and action | |
AU2001283486A1 (en) | Methods of modulating wound healing and angiogenesis | |
AU2876000A (en) | Tyrosine kinase inhibitors and methods of using the same | |
IL144762A0 (en) | Liposome composition and method for administration of radiosensitizer | |
HUP0301797A3 (en) | Inhibition of angiogenesis and tumor growth |